Nintedanib Onkogen

Nintedanib, the active ingredient in Nintedanib Onkogen, is a tyrosine kinase inhibitor presented as an oral formulation for oral use. It is employed in the management of idiopathic pulmonary fibrosis and certain forms of non‑small cell lung cancer.

GNH USA supplies Nintedanib Onkogen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution. Customers benefit from consistent product availability and regulatory support across multiple regions.

Nintedanib acts on fibrotic and angiogenic pathways, making it useful in several pulmonary and oncologic conditions. - Idiopathic pulmonary fibrosis: slows decline in lung function and reduces disease progression. - Non‑small cell lung cancer: used in combination therapy to inhibit tumor angiogenesis and growth. - Systemic sclerosis‑associated interstitial lung disease: helps preserve lung capacity and delay functional deterioration.

Nintedanib may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea: feeling of stomach upset. - Diarrhea: frequent loose stools. - Vomiting: episodes of emesis. - Decreased appetite: reduced desire to eat. - Abdominal pain: discomfort in the stomach area. - Weight loss: unintended reduction in body weight.

Serious or Rare Side Effects: - Elevated liver enzymes: signs of hepatic injury. - Bleeding events: increased risk of gastrointestinal or other hemorrhage. - Cardiovascular complications: such as hypertension or arterial thrombotic events. - Severe infections: opportunistic or serious bacterial infections. - Gastrointestinal perforation: rare but potentially life‑threatening.

When prescribing Nintedanib, clinicians should observe several precautionary measures to ensure patient safety. - Liver function monitoring: assess transaminases before and during therapy. - Cardiovascular assessment: evaluate blood pressure and cardiac risk factors. - Bleeding risk evaluation: avoid use in patients with active bleeding or high anticoagulant exposure. - Gastrointestinal health: monitor for severe diarrhea or abdominal pain. - Pregnancy and lactation: contraindicated unless benefits outweigh risks (consult specialist). - Store at below 25°C: keep in the original pack, protect from moisture.

Nintedanib can interact with other medicines, influencing its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase nintedanib exposure. - Anticoagulants (e.g., warfarin): heightened risk of bleeding. - Antiplatelet agents (e.g., aspirin, clopidogrel): additive bleeding potential.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., erythromycin, clarithromycin): may modestly raise drug levels. - P‑gp inhibitors (e.g., verapamil, amiodarone): could increase exposure. - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce therapeutic effect.